Floatz logo

Nivestim

Acute Undifferentiated Leukemia

Fred Hutchinson Cancer Centerprotein_peptidePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

32 Active assets in the Acute Undifferentiated Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
Vincristine sulfate
M.D. Anderson Cancer Center
Phase 3BB
Cytarabine
Fred Hutchinson Cancer Center
Phase 3BB
Dexasone
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BB
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
Phase 3BB

View all 50 →

Same molecule, other indications

Nivestim is also rated in:

Burkitt lymphomaActive
BBB
Indicative · Phase 4
78 / 100
View asset →
neutropeniaActive
BBB
Indicative · Phase 4
76 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative · Phase 4
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →